A human monoclonal antibody blocking SARS-CoV-2 infection

Article activity feed

1. 

   ScreenIT

   Jun 5, 2020

   SciScore for 10.1101/2020.03.11.987958: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Cells were subsequently incubated with S1B and mAb mixture for 1 h on ice, followed by incubation with Alexa Fluor 594 conjugated goat anti-human IgG antibodies (Invitrogen, Thermo Fisher Scientific) for 45 min at room temperature.	anti-human IgG suggested: None
   Plates were washed three times and incubated with HRP-conjugated goat anti-human secondary antibody (ITK Southern Biotech) diluted 1:2000 in blocking buffer for 1 hour at room temperature.	anti-human …

   SciScore for 10.1101/2020.03.11.987958: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Cells were subsequently incubated with S1B and mAb mixture for 1 h on ice, followed by incubation with Alexa Fluor 594 conjugated goat anti-human IgG antibodies (Invitrogen, Thermo Fisher Scientific) for 45 min at room temperature.	anti-human IgG suggested: None
   Plates were washed three times and incubated with HRP-conjugated goat anti-human secondary antibody (ITK Southern Biotech) diluted 1:2000 in blocking buffer for 1 hour at room temperature.	anti-human secondary antibody ( ITK suggested: None
   An HRP-conjugated anti-StrepMAb (IBA, Cat.no: 2-1509-001) antibody was used to corroborate equimolar coating of the Strep-tagged spike antigens.	anti-StrepMAb suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Recombinant human 47D11 mAb and previously described Isotype-control (anti-Streptag mAb) or 7.7G6 mAb were produced in HEK-293T cells following transfection with pairs of the IgG1 heavy and light chain expression plasmids according to protocols from InvivoGen.	HEK-293T suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)
   The mixture was then added to VeroE6 cells and incubated for 1 hr, after which the cells were washed and further incubated in medium for 8 hrs.	VeroE6 suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
   Software and Algorithms
   Sentences	Resources
   The results were analysed by FlowJo (version 10).	FlowJo suggested: (FlowJo, RRID:SCR_008520)
   The half maximal inhibitory concentrations (IC50) were determined using 4-parameter logistic regression (GraphPad Prism version 8).	GraphPad suggested: (GraphPad Prism, RRID:SCR_002798)
   Half-maximum effective concentration (EC50) binding values were calculated by non-linear regression analysis on the binding curves using GraphPad Prism (version 8).	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
2. Version published to 10.1038/s41467-020-16256-y

   May 4, 2020
3. 

   Version published to 10.1101/2020.03.11.987958v1 on bioRxiv

   Mar 12, 2020